186 related articles for article (PubMed ID: 35317513)
1. A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy.
Muhammad N; Wang R; Li W; Zhang Z; Chang Y; Hu Y; Zhao J; Zheng X; Mao Q; Xia H
Mol Ther Oncolytics; 2022 Mar; 24():729-741. PubMed ID: 35317513
[TBL] [Abstract][Full Text] [Related]
2. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
3. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
5. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
6. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
[TBL] [Abstract][Full Text] [Related]
7. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
8. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
[TBL] [Abstract][Full Text] [Related]
9. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
10. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
11. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
12. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
13. Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor ß towards B-Acute Myeloid Leukaemia Blasts.
Ghamari A; Pakzad P; Majd A; Ebrahimi M; Hamidieh AA
Cell J; 2021 Nov; 23(6):650-657. PubMed ID: 34939758
[TBL] [Abstract][Full Text] [Related]
14. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
15. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
16. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Bielamowicz K; Fousek K; Byrd TT; Samaha H; Mukherjee M; Aware N; Wu MF; Orange JS; Sumazin P; Man TK; Joseph SK; Hegde M; Ahmed N
Neuro Oncol; 2018 Mar; 20(4):506-518. PubMed ID: 29016929
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
An Z; Hu Y; Bai Y; Zhang C; Xu C; Kang X; Yang S; Li W; Zhong X
Oncoimmunology; 2021; 10(1):1960728. PubMed ID: 34408922
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose.
Lin Q; Ba T; Ho J; Chen D; Cheng Y; Wang L; Xu G; Xu L; Zhou Y; Wei Y; Li J; Ling F
Front Oncol; 2021; 11():694941. PubMed ID: 34235085
[TBL] [Abstract][Full Text] [Related]
19. T cells redirected to EphA2 for the immunotherapy of glioblastoma.
Chow KK; Naik S; Kakarla S; Brawley VS; Shaffer DR; Yi Z; Rainusso N; Wu MF; Liu H; Kew Y; Grossman RG; Powell S; Lee D; Ahmed N; Gottschalk S
Mol Ther; 2013 Mar; 21(3):629-37. PubMed ID: 23070117
[TBL] [Abstract][Full Text] [Related]
20. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
